Effect of imipramine and prolyl endopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on activity of proline-specific peptidases in the brain of ratswith experimental anxious-depressive syndrome

Bulletin of Experimental Biology and Medicine

Volumn 152, Issue 4, 2012, Pages 409-412

  Khlebnikova, N N ^a   Krupina, N A ^a   Kushnareva, E Yu ^a   Zolotov, N N ^b   Kryzhanovskii, G N ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Brain structures; Depression; Dipeptidyl peptidase IV; Prolyl endopeptidase; Rats

Indexed keywords

BENZYLOXYCARBONYL METHIONYL 2 CYANOPYRROLIDINE; DIPEPTIDYL PEPTIDASE IV; IMIPRAMINE; PEPTIDASE; PROLINE; PROLYL ENDOPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; EMOTION; ENZYME ACTIVITY; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; ONTOGENY; POSTNATAL GROWTH; RAT; REINFORCEMENT;

EID: 85027955433     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-012-1540-z     Document Type: Article

References (15)

1. N. A. Krupina, N. N. Zolotov, N. G. Bogdanova, et al., Byull. Eksp. Biol. Med., 142, No. 11, 497-499 (2006).
2. N. A. Krupina, E. Yu. Kushnareva, N. N. Khlebnikova, et al., Ibid., 147, No. 3, 254-260 (2009).
3. N. A. Krupina, I. N. Orlova, and G. N. Kryzhanovskii, Ibid., 120, No. 8, 160-164 (1995).
4. N. A. Krupina, I. N. Orlova, and G. N. Kryzhanovskii, Zh. Vyssh. Nervn. Deyat., 49, No. 5, 865-876 (1999).
5. E. Yu. Kushnareva, N. A. Krupina, N. N. Khlebnikova, et al., Byull. Eksp. Biol. Med., 151, No. 6, 619-623 (2011).
6. N. N. Khlebnikova, N. A. Krupina, I. N. Orlova, et al., Ibid., 147, No. 1, 27-31 (2009).
7. L. F. Barrett, K. A. Lindquist, E. Bliss-Moreau, et al., Perspect. Psychol. Sci., 2, No. 3, 297-311 (2007).
8. J. R. Kapoor and C. D. Sladek, Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, No. 1, 69-78 (2001).
9. J. E. Knuuttila, P. Törönén, and E. Castren, Neurochem. Res., 6, 1235-1244 (2004).
10. M. Maes and S. Bonaccorso, Acta Psychiatr. Scand., 109, No. 2, 126-131 (2004).
11. M. Maes, F. Goossens, S. Scharpé, et al., Psychiatry Res., 58, No. 3, 217-225 (1995).
12. P. T. Männistö, P. Tuomainen, O. Kutepova, et al., Pharmacol. Biochem. Behav., 49, No. 1, 33-40 (1994).
13. G. Racagni and M. Popoli, Dialogues Clin. Neurosci., 10, No. 4, 385-400 (2008).
14. I. Schulz, B. Gerhartz, A. Neubauer, et al., Eur. J. Biochem., 269, No. 23, 5813-5820 (2002).
15. S. R. Sesack and A. A. Grace, Neuropsychopharmacology, 35, No. 1, 27-47 (2010).